Novo Nordisk A/S Common Stock (NVO)

62.33
+5.21 (9.12%)
NYSE · Last Trade: Jan 17th, 1:47 AM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
The Arctic Ultimatums: Trump’s Greenland Bid Sparks Global Trade War and NATO Crisis
WASHINGTON D.C. — In a dramatic escalation of his "America First" foreign policy, President Donald Trump has moved beyond mere interest to a formal demand for the acquisition of Greenland, threatening a wave of crippling tariffs against any nation—including long-standing NATO allies—that opposes the bid. As of January
Via MarketMinute · January 16, 2026
Eli Lilly vs. Novo Nordisk: Which Is the Better Stock Buy?fool.com
The choice isn't that hard.
Via The Motley Fool · January 16, 2026
NVO Shares Rise On Strong Kickstart For Wegovy Pill In US: Retail Eyes Up To $110 As ‘Fair Value’stocktwits.com
Via Stocktwits · January 16, 2026
NVO Stock Is Rising Pre-Market – What Is The Wegovy News Driving Novo Nordisk Shares?stocktwits.com
The United Kingdom’s Medicines and Healthcare products Regulatory Agency on Friday announced that it had approved a maximum dose of up to 7.2 milligrams a week for Novo’s Wegovy earlier this month.
Via Stocktwits · January 16, 2026
AbbVie Seeks To Grow Obesity Drug Portfolio — Retail Touts Drugmaker As Big Competition To Lillystocktwits.com
Via Stocktwits · January 14, 2026
VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Dealsstocktwits.com
Via Stocktwits · January 14, 2026
FDA Clears Popular Weight-Loss Drugs Of Suicide Risk After Review Of Over 100K Patients, Asks Drugmakers To Remove Warningsstocktwits.com
Via Stocktwits · January 13, 2026
Eli Lilly’s $1.2 Billion Acquisition of Ventyx Biosciences: Bridging the Gap Between Weight Loss and Chronic Inflammation
In a bold move to solidify its dominance in the cardiometabolic market, Eli Lilly and Company (NYSE:LLY) announced on January 7, 2026, that it has entered into a definitive agreement to acquire Ventyx Biosciences (NASDAQ:VTYX) for approximately $1.2 billion. The all-cash transaction, priced at $14.00 per
Via MarketMinute · January 15, 2026
Novo Nordisk Stock Dips As Company Faces GLP-1 Antitrust Lawsuitbenzinga.com
Novo Nordisk A/S (NYSE:NVO) shares are trading lower on Thursday after the company was hit with a lawsuit from compounding pharmacy Strive Specialties.
Via Benzinga · January 15, 2026
Eli Lilly Stock Slips After Antitrust Lawsuit Against GLP-1 Providersbenzinga.com
Eli Lilly And Co (NYSE:LLY) and Novo Nordisk (NYSE:NVO), are reportedly being sued in Texas by compounding pharmacy Strive Specialties
Via Benzinga · January 15, 2026
Slimmer Waistlines, Fatter Margins: Jefferies Says Airline Companies Will Profit From America’s Weight-Loss Boomstocktwits.com
Via Stocktwits · January 14, 2026
Why Is HIMS Stock Slipping Premarket Today?stocktwits.com
Via Stocktwits · January 12, 2026
Healthcare Sector Stages Resilient Rebound as Policy Clarity and GLP-1 Innovations Fuel Investor Optimism
The U.S. healthcare sector has entered 2026 on a remarkably strong footing, staging a decisive rebound after a tumultuous 2025. This resurgence is being driven by a rare alignment of legislative progress and pharmaceutical innovation. On January 8, 2026, the U.S. House of Representatives passed a crucial bill
Via MarketMinute · January 14, 2026
Is It Time to Dump Your Shares of Eli Lilly?fool.com
What happens with Eli Lilly's GLP-1 shot now that Novo Nordisk has come out with a GLP-1 pill?
Via The Motley Fool · January 14, 2026
Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concernsmarketbeat.com
Via MarketBeat · January 13, 2026
The Great Recalibration: Why 2026 Could Be Healthcare’s Year to Rebound
For the past two years, the U.S. healthcare sector has been the forgotten stepchild of the equity markets. As the S&P 500 (SPX) surged on the back of an artificial intelligence gold rush and a resilient tech economy, healthcare investors were left nursing a "double-digit hangover." In 2024,
Via MarketMinute · January 13, 2026
Amgen at the Crossroads: MariTide, Market Volatility, and the Quest for Obesity Dominance
Date: January 13, 2026 Introduction Amgen Inc. (NASDAQ: AMGN) finds itself at a historic crossroads. Long regarded as the "blue-chip" anchor of the biotechnology sector, the Thousand Oaks-based giant is currently attempting one of the most ambitious pivots in its 45-year history. While the company has built its multi-billion-dollar empire on bone health, oncology, and [...]
Via PredictStreet · January 13, 2026
Eli Lilly vs Novo Nordisk: Which Company Will Dominate the Weight Loss Drug Market in 2026?fool.com
Both companies now aim to win in the oral weight loss drug market.
Via The Motley Fool · January 13, 2026
Can Novo Nordisk Unseat Eli Lilly as the Weight Loss Drug Leader in 2026?fool.com
The gap may be too hard to close in the next 12 months.
Via The Motley Fool · January 13, 2026
Why Tempus AI Stock Rose Todayfool.com
The data provider's artificial intelligence-driven solutions are accelerating drug discovery.
Via The Motley Fool · January 12, 2026
Beyond the Protein: How AlphaFold 3 Redefined the Blueprint of Life and Accelerated the Drug Discovery Revolution
In the two years since its unveiling, AlphaFold 3 (AF3) has fundamentally transformed the landscape of biological research, moving the industry from simple protein folding to a comprehensive "all-atom" understanding of life. Developed by Google DeepMind and its commercial arm, Isomorphic Labs—both subsidiaries of Alphabet (NASDAQ: GOOGL)—the model has effectively bridged the gap between computational [...]
Via TokenRing AI · January 12, 2026
Anthropic Launches “Claude for Healthcare”: A Paradigm Shift in Medical AI Integration and HIPAA Security
On January 11, 2026, Anthropic officially unveiled Claude for Healthcare, a specialized suite of artificial intelligence tools designed to bridge the gap between frontier large language models and the highly regulated medical industry. Announced during the opening of the J.P. Morgan Healthcare Conference, the platform represents a strategic pivot for Anthropic, moving beyond general-purpose AI [...]
Via TokenRing AI · January 12, 2026
From Silicon to Syringes: Nvidia’s AI Dominance Solidified Through Landmark Eli Lilly Alliance
In a move that signals the definitive convergence of high-performance computing and biotechnology, NVIDIA Corporation (NASDAQ: NVDA) and Eli Lilly and Company (NYSE: LLY) announced a massive $1 billion "co-innovation" partnership at the J.P. Morgan Healthcare Conference on January 12, 2026. This five-year strategic alliance aims to re-engineer the
Via MarketMinute · January 12, 2026
The Convergence of Silicon and Science: Eli Lilly and Nvidia Unveil $1 Billion AI Co-Innovation Lab at JPM26
In a move that signals the definitive arrival of the "AI-first" era for the pharmaceutical industry, Eli Lilly and Company (NYSE:LLY) and NVIDIA Corporation (NASDAQ:NVDA) announced a massive expansion of their strategic partnership today at the 44th Annual J.P. Morgan Healthcare Conference (JPM26). The centerpiece of the
Via MarketMinute · January 12, 2026
An Investor's Guide to 2026fool.com
What does the new year bring to investors?
Via The Motley Fool · January 12, 2026